

TILLOTTS UK LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO MEMBERS OF THE PUBLIC AND PATIENT ORGANISATION FOR FINANCIAL YEAR 2024

Members of the Public\*:

Number of Members of the Public Contracted	Description of Financial Support from Tillotts Pharma UK Ltd	Transfer of Value type	Value (£)
2	Patient speaker at education day	Fees	600
		Expenses	91.3
	Disease awareness video filming	Fees	380
		Expenses	61.75
		Total	1133.05

\*Other Members of the Public including Caregivers, Patient Advocates, and Models etc

Patient organisation:

Name of Patient Organisation	Description of Financial Support from Tillotts Pharma UK Ltd	Value (£)
#GETYOURBELLYOUT	Advisor for public awareness campaign	100
#GETYOURBELLYOUT	Advisor for public awareness campaign	200
#GETYOURBELLYOUT	Advisor for public awareness campaign	100
#GETYOURBELLYOUT	Speaker at Tillotts UK event	1800
	Total	2200

## **Methodological Notes**

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding. Inclusion of this methodological note alongside the disclosure data is also mandated by the ABPI Code of Practice in Clause 28.6.

### **Disclosure by Tillotts Pharma of payments to UK health professionals, other relevant decision makers, and health care organisations in 2024**

The ABPI Code of Practice mandates the public disclosure in 2025 of certain transfers of value made during 2024 to UK health professionals, other relevant decision makers, and health care organisations. Where permission to disclose transfers of value is refused by individual health professionals or other relevant decision makers, the transfer of value made to them is disclosed in an aggregated fashion. The disclosure data is published on a central platform, hosted by the ABPI and made available to anyone who requests access.

### **Disclosure by Tillotts Pharma of payments to patient organisations in 2024**

The ABPI Code of Practice mandates the public disclosure in 2025 of certain transfers of value made during 2024 to patient organisations. The disclosure data is published on the Disclosure page of Tillotts Pharma AG website, [www.tillotts.com](http://www.tillotts.com). The ABPI Code requirements on disclosure specific to patient organisations is set out in Clause 29.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding. Inclusion of this methodological note alongside the disclosure data is also mandated by the ABPI Code of Practice in Clause 29.1.

### **Disclosure by Tillotts Pharma of payments to public, including patients and journalists, in 2024**

The ABPI Code of Practice mandates the public disclosure in 2025 of certain transfers of value made during 2024 to members of the public including patients and journalists. The disclosure data is published on the Disclosure page of Tillotts Pharma AG website, [www.tillotts.com](http://www.tillotts.com). The ABPI Code requirements on disclosure specific to patient organisations is set out in Clause 30.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding. Inclusion of this methodological note alongside the disclosure data is also mandated by the ABPI Code of Practice in Clause 30.1.

## **VAT**

VAT is excluded from all disclosures of transfer of value.

## **Currency**

All disclosures are made in Pounds Sterling (£). Where the original payment was made in another currency (for example Swiss Francs or Euros (€)), the sum was converted to pounds at the exchange rate prevailing at the time of the original payment or were converted to pounds at the average annual exchange rate of the European Central Bank for calendar year 2024.

## **Consolidated Disclosures of the Corporate Group and Cross border payments**

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same

multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. The disclosures represent payments by Tillotts Pharma UK Ltd, Tillotts Pharma AG (of which Tillotts Pharma UK Ltd. is a wholly owned subsidiary), and other overseas Tillotts affiliates. These methodology notes apply equally to the disclosures made by Tillotts Pharma AG and Tillotts Pharma UK Ltd .

## **Data Protection**

### *Consent to disclose data*

In countries where it is required by applicable data protection laws, Tillotts has taken all reasonable steps to obtain consents from the HCPs, ORDMs, and HCOs, as applicable, to publicly disclose payments and other transfers of value. In accordance with EFPIA guidance, partial consents are not acceptable. If consent is not provided, the data will be reported on an aggregate level only.

### *Consent collection and withdrawal*

Tillotts respects applicable data protection laws. If a stakeholder withdraws the provided consent, Tillotts will adjust the publication accordingly within a reasonable time.

## **Data included**

The data disclosed by Tillotts Pharma is consistent with the requirements of the ABPI Code of Practice. The data can be categorised as follows:

### *Support for health professionals to attend educational events*

Disclosed data includes all travel costs, such as flights, transfers from airport to hotel or congress venue, train and underground/metro journeys. The disclosure data also includes accommodation costs such as hotel rooms, but does not include food and drink costs. The disclosure data also includes the registration fee, where applicable, for the health professional to be registered to attend the educational event. These data relate to congresses held during 2024, even if invoices relating to payments made were settled in the next calendar year.

### *Payment of consultants who provide services to Tillotts*

Disclosed data includes the payment of honoraria to UK health professionals who provided services to Tillotts during 2024, even if payment was made in the next calendar year. Where applicable, the disclosure data also includes payment of reasonable expenses to such consultants in the delivery of their services, such as travel expenses or accommodation expenses.

The number of recipients disclosed in aggregate as a percentage in columns V-Y has been calculated as a percentage of recipients for that payment type (e.g. No. of aggregated recipients of consultancy fees ÷ Total recipients of consultancy fees x 100).

### *Donations, grants and sponsorship to health care organisations*

Disclosed data includes transfers of value to UK health care organisations for the purpose of supporting healthcare, scientific research or education, and costs related to events/meetings. Tillotts Pharma's support was contingent upon all such transfers of value being disclosed publicly.

*Contracted services, donations, grants and sponsorship provided to patient organisations*

Disclosed data includes transfers of value to patient organisations, including in relation to events/meetings. Tillotts Pharma's support was contingent upon all such transfers of value being disclosed publicly.

*Contracted services provided by public, including patients and journalists*

Disclosed data includes transfers of value to public, including speaking at meetings, writing articles, and participating in market research where such participation involves remuneration and/or travel.

*Research & Development*

Research & Development transfers of value are disclosed in the aggregate and encompass transfers of value to UK health professionals and UK health care organisations related to non-clinical studies (as defined in the OECD Principles of Good Laboratory Practice), clinical trials (as defined in Regulation 536/2014), non-interventional studies (prospective in nature and involving the collection of data from, or on behalf of, individual or groups of health professionals specifically for the study), as well as costs that are subsidiary to these activities.